CN101014246A - 地西他滨多晶型物的组合物和制剂及其使用方法 - Google Patents

地西他滨多晶型物的组合物和制剂及其使用方法 Download PDF

Info

Publication number
CN101014246A
CN101014246A CNA2005800299116A CN200580029911A CN101014246A CN 101014246 A CN101014246 A CN 101014246A CN A2005800299116 A CNA2005800299116 A CN A2005800299116A CN 200580029911 A CN200580029911 A CN 200580029911A CN 101014246 A CN101014246 A CN 101014246A
Authority
CN
China
Prior art keywords
decitabine
polymorph
polymorphs
heat absorption
decitabine polymorphs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800299116A
Other languages
English (en)
Chinese (zh)
Inventor
S·雷德卡
R·乔希－汉戈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Pharmaceuticals Inc
Original Assignee
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35600347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101014246(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Supergen Inc filed Critical Supergen Inc
Publication of CN101014246A publication Critical patent/CN101014246A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CNA2005800299116A 2004-07-13 2005-07-12 地西他滨多晶型物的组合物和制剂及其使用方法 Pending CN101014246A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/890,828 2004-07-13
US10/890,828 US20060014949A1 (en) 2004-07-13 2004-07-13 Compositions and formulations of decitabine polymorphs and methods of use thereof

Publications (1)

Publication Number Publication Date
CN101014246A true CN101014246A (zh) 2007-08-08

Family

ID=35600347

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800299116A Pending CN101014246A (zh) 2004-07-13 2005-07-12 地西他滨多晶型物的组合物和制剂及其使用方法

Country Status (7)

Country Link
US (1) US20060014949A1 (https=)
EP (1) EP1765076A4 (https=)
JP (1) JP5159307B2 (https=)
CN (1) CN101014246A (https=)
AU (3) AU2005271814B2 (https=)
CA (1) CA2573332A1 (https=)
WO (1) WO2006017278A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101781347A (zh) * 2009-12-21 2010-07-21 南京卡文迪许生物工程技术有限公司 地西他滨多晶型物和药用组合物
CN103191144A (zh) * 2013-04-25 2013-07-10 李伟丽 一种治疗癌症的药物组合物及应用
CN108635367A (zh) * 2011-08-30 2018-10-12 阿斯泰克斯制药公司 地西他滨衍生物制剂
CN115989229A (zh) * 2020-07-23 2023-04-18 南方研究院 5-氮杂-4’-硫代-2’-脱氧胞苷的多晶型物
CN119943194A (zh) * 2023-11-03 2025-05-06 中国石油天然气股份有限公司 一种分子筛晶胞参数确定方法和装置

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
JP5687687B2 (ja) 2009-04-06 2015-03-18 大塚製薬株式会社 癌を治療するための（２’−デオキシ−リボフラノシル）−１，３，４，７−テトラヒドロ−（１，３）ジアゼピン−２−オン誘導体
WO2010129211A2 (en) * 2009-04-27 2010-11-11 Dr. Reddy's Laboratories Ltd. Preparation of decitabine
EP2766041B1 (en) 2011-10-12 2018-12-05 Children's Medical Center Corporation Combinatorial compositions and methods of treating hemoglobinopathies
US20140094598A1 (en) 2012-10-01 2014-04-03 Johnson Matthey Public Limited Company Method for the purification of decitabine
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
WO2019025256A1 (en) 2017-08-01 2019-02-07 Bayer Aktiengesellschaft COMBINATION OF MIDH1 INHIBITORS AND DNA HYPOMETHYLATION (AHM) AGENTS
KR20200035438A (ko) 2017-08-03 2020-04-03 오쓰까 세이야꾸 가부시키가이샤 약물 화합물 및 이의 정제 방법
JP7089603B2 (ja) 2018-06-11 2022-06-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼疾患を治療するための脱メチル化
PH12022552250A1 (en) 2020-02-25 2023-11-13 Otsuka Pharma Co Ltd Combination decitabine and cedazuridine solid oral dosage forms
EP4138843A4 (en) 2020-04-23 2024-07-10 Southern Research Institute COMPOSITION FOR THE TREATMENT OF BLOOD CANCER USING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND USES THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1050899A (https=) * 1963-12-22
CH527207A (de) * 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) * 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
JPS5213741B2 (https=) * 1972-05-22 1977-04-16
JPS5527077A (en) * 1978-08-16 1980-02-26 Shin Meiwa Ind Co Ltd Solids scraper for sludge dehydrator
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
KR101150250B1 (ko) * 2001-03-01 2012-06-12 아보트 래버러토리즈 시스-ｆｔｃ의 다형 및 기타 결정형
US20040162263A1 (en) * 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101781347A (zh) * 2009-12-21 2010-07-21 南京卡文迪许生物工程技术有限公司 地西他滨多晶型物和药用组合物
CN108635367A (zh) * 2011-08-30 2018-10-12 阿斯泰克斯制药公司 地西他滨衍生物制剂
CN108635367B (zh) * 2011-08-30 2020-08-21 阿斯泰克斯制药公司 地西他滨衍生物制剂
CN103191144A (zh) * 2013-04-25 2013-07-10 李伟丽 一种治疗癌症的药物组合物及应用
CN115989229A (zh) * 2020-07-23 2023-04-18 南方研究院 5-氮杂-4’-硫代-2’-脱氧胞苷的多晶型物
CN119943194A (zh) * 2023-11-03 2025-05-06 中国石油天然气股份有限公司 一种分子筛晶胞参数确定方法和装置

Also Published As

Publication number Publication date
AU2011200540A8 (en) 2011-03-10
WO2006017278A1 (en) 2006-02-16
AU2011200540A1 (en) 2011-03-03
AU2011200539A1 (en) 2011-03-03
JP2008506690A (ja) 2008-03-06
EP1765076A1 (en) 2007-03-28
JP5159307B2 (ja) 2013-03-06
EP1765076A4 (en) 2009-04-22
US20060014949A1 (en) 2006-01-19
AU2005271814B2 (en) 2010-11-11
CA2573332A1 (en) 2006-02-16
AU2005271814A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
AU2011200540A8 (en) Compositions and formulations of decitabine polymorphs and methods of use thereof
EP2181988B1 (en) Pharmaceutical Compositions based on Crystalline Form I of 5-Azacytidine
US7858594B2 (en) Crystalline and amorphous forms of beta-L-2′-deoxythymidine
EP3292115B1 (en) Crystalline form of fused pyridine derivative's maleate and uses thereof
US6696458B2 (en) Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
TW201904966A (zh) Fgfr抑制劑之結晶形式及其製備方法
WO2006037024A2 (en) Salts of decitabine
EP1788874A2 (en) Salts of 5-azacytidine
EP3233857A2 (en) Solid state forms of fused heteroaromatic pyrrolidinones
TW201512192A (zh) 喹唑啉衍生物之固態形式及其作爲ｂｒａｆ抑制劑之用途
SG172782A1 (en) Anti-inflammatory macrolide
KR20160018714A (ko) 이코티닙 포스페이트의 신규한 다형체 형태 및 이의 용도
JP5616355B2 (ja) モルフィン−６−グルクロニドの２環式誘導体、この調製方法および治療法でのこの使用
HK1184163A (en) Amorphous form of beta- l-2'-deoxythymidine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication